文献速递心律失常

房颤患者使用不同口服抗凝药的骨折风险:真实世界全国性队列研究

Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study.
PubMed 文献 · Eur Heart J · 2020-01-01

该研究基于台湾全民健康保险研究数据库,纳入2012至2016年新诊断房颤并接受NOAC或华法林的成人患者,随访至2017年。结果显示,与华法林相比,NOAC与骨折风险降低相关(aHR=0.84,95%CI 0.77-0.93;P<0.001),达比加群、利伐沙班和阿哌沙班均显示骨折风险降低。

要点

  • 房颤患者使用NOAC较华法林骨折风险降低(aHR=0.84)。
  • 达比加群、利伐沙班、阿哌沙班均与骨折风险降低相关。
  • 有口服抗凝指征时,优先考虑NOAC以降低骨折风险。

核心结论

  • 与华法林相比,房颤患者使用NOAC与骨折风险降低相关。
  • 有口服抗凝指征时,应考虑NOAC而非华法林以降低骨折风险。

研究设计与样本

  • 真实世界全国性回顾性队列研究,使用台湾全民健康保险研究数据库。
  • 纳入2012至2016年新诊断房颤并接受NOAC或华法林的成人患者,随访至2017年。
  • NOAC组按药物分为达比加群、利伐沙班和阿哌沙班亚组,每项头对头比较均进行倾向评分匹配。
  • 采用Cox回归分析及共享 frailty 模型计算髋部、椎体和肱骨/前臂/腕部骨折的调整风险比。

主要发现

  • 与华法林相比,NOAC与骨折风险降低相关(aHR=0.84,95%CI 0.77-0.93;P<0.001)。
  • 达比加群与骨折风险降低相关(aHR=0.88,95%CI 0.78-0.99;P=0.027)。
  • 利伐沙班与骨折风险降低相关(aHR=0.81,95%CI 0.72-0.90;P<0.001)。
  • 阿哌沙班与骨折风险降低相关(aHR=0.67,95%CI 0.52-0.87;P=0.003)。
  • 纳入所有合格患者(不进行倾向评分匹配)的分析结果相似。

临床怎么用

  • 对于有口服抗凝指征的房颤患者,优先选择NOAC而非华法林以降低骨折风险。
  • 选择具体NOAC时,可考虑阿哌沙班、利伐沙班或达比加群均与骨折风险降低相关。

局限性

  • 需要进一步研究探讨潜在机制并阐明因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To evaluate the fracture risk among patients with atrial fibrillation (AF) treated with non-vitamin K antagonist oral anticoagulants (NOACs) or warfarin. METHODS AND RESULTS: We conducted a real-world nationwide retrospective cohort study using Taiwan's National Health Insurance Research Database. All adult patients in Taiwan newly diagnosed with AF between 2012 and 2016 who received NOACs or warfarin were enrolled and followed up until 2017. Patients treated with NOACs were sub-grouped according to the NOAC used (dabigatran, rivaroxaban, and apixaban). Propensity score matching was performed for each head-to-head comparison. Cox regression analysis, with a shared frailty model, was used to calculate the adjusted hazard ratios (aHRs) for hip, vertebral, and humerus/forearm/wrist fractures. After matching, 19 414 patients were included (9707 in each NOAC and warfarin groups). The median follow-up time was 2.4 years. Compared with warfarin, NOACs were associated with a reduced fracture risk [aHR = 0.84, 95% confidence interval (CI) = 0.77-0.93; P < 0.001]. Sub-analyses revealed that each NOAC, namely dabigatran (aHR = 0.88, 95% CI = 0.78-0.99; P = 0.027), rivaroxaban (aHR = 0.81, 95% CI = 0.72-0.90; P < 0.001), and apixaban (aHR = 0.67, 95% CI = 0.52-0.87; P = 0.003), had a reduced fracture risk. Analyses including all eligible patients, without propensity score matching, generated similar results. CONCLUSION: Compared with warfarin, NOAC was associated with a reduced fracture risk among AF patients. Therefore, if oral anticoagulants are indicated, NOACs rather than warfarin should be considered to lower the risk of fractures. However, further studies are needed to investigate the underlying mechanisms and elucidate causality.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Huang HK, Liu PP, Hsu JY, et al. Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study. Eur Heart J. 2020. PMID: 32006423. doi:10.1093/eurheartj/ehz952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。